Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1740.60
NRIFF's Cash-to-Debt is ranked higher than
71% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. NRIFF: 1740.60 )
Ranked among companies with meaningful Cash-to-Debt only.
NRIFF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 6.77 Max: No Debt
Current: 1740.6
Equity-to-Asset 0.79
NRIFF's Equity-to-Asset is ranked higher than
77% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NRIFF: 0.79 )
Ranked among companies with meaningful Equity-to-Asset only.
NRIFF' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.42  Med: 0.77 Max: 0.99
Current: 0.79
-0.42
0.99
Piotroski F-Score: 5
Altman Z-Score: -0.65
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -16.34
NRIFF's Operating Margin % is ranked lower than
81% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. NRIFF: -16.34 )
Ranked among companies with meaningful Operating Margin % only.
NRIFF' s Operating Margin % Range Over the Past 10 Years
Min: -331.76  Med: -54.94 Max: 42.55
Current: -16.34
-331.76
42.55
Net Margin % 9.28
NRIFF's Net Margin % is ranked higher than
61% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. NRIFF: 9.28 )
Ranked among companies with meaningful Net Margin % only.
NRIFF' s Net Margin % Range Over the Past 10 Years
Min: -306.38  Med: -55.7 Max: 295.55
Current: 9.28
-306.38
295.55
ROE % 8.92
NRIFF's ROE % is ranked higher than
58% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. NRIFF: 8.92 )
Ranked among companies with meaningful ROE % only.
NRIFF' s ROE % Range Over the Past 10 Years
Min: -978.57  Med: -43.21 Max: 113.73
Current: 8.92
-978.57
113.73
ROA % 7.34
NRIFF's ROA % is ranked higher than
69% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. NRIFF: 7.34 )
Ranked among companies with meaningful ROA % only.
NRIFF' s ROA % Range Over the Past 10 Years
Min: -92.28  Med: -33.97 Max: 88.96
Current: 7.34
-92.28
88.96
ROC (Joel Greenblatt) % -154.26
NRIFF's ROC (Joel Greenblatt) % is ranked lower than
84% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. NRIFF: -154.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NRIFF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -580.94  Med: -456.86 Max: 3057.7
Current: -154.26
-580.94
3057.7
3-Year Revenue Growth Rate -11.40
NRIFF's 3-Year Revenue Growth Rate is ranked lower than
85% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. NRIFF: -11.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NRIFF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -31.6  Med: -5.45 Max: 48.7
Current: -11.4
-31.6
48.7
3-Year EBITDA Growth Rate -23.90
NRIFF's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. NRIFF: -23.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NRIFF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -37.1  Med: -22.1 Max: 16.4
Current: -23.9
-37.1
16.4
3-Year EPS without NRI Growth Rate -25.00
NRIFF's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. NRIFF: -25.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NRIFF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.1  Med: -17.5 Max: 15.7
Current: -25
-48.1
15.7
GuruFocus has detected 2 Warning Signs with Nuvo Pharmaceuticals Inc $NRIFF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NRIFF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with NRIFF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 3741
Compare:NAS:JNP, OTCPK:MGWFF, NAS:PSDV, NAS:IMMY, NAS:GALT, OTCPK:MGCLF, NAS:MEIP, NAS:OREX, NAS:ADMP, OTCPK:ACNNF, NAS:PTX, NAS:FCSC, NAS:SPHS, NAS:SNOA, OTCPK:AOLS, NAS:ARDM, OTCPK:KAYS, NAS:BPTH, OTCPK:CBICF, NAS:APRI » details
Traded in other countries:NRI.Canada, 23N.Germany,
Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.

Nuvo Research, Inc. was incorporated on August 22, 1983 under the laws of the Province of Ontario. The Company is a publicly traded Canadian specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group (formerly the Pain Group) and the Immunology Group. The TPT Group has four commercialized products, a pipeline of products at various stages of development focusing on the following therapeutic areas: pain, dermatology, central nervous system (CNS) and endocrinology and four topical and transdermal drug delivery (TTDD) platforms. The Immunology Group has two commercialized products, a development program for the treatment of allergic rhinitis and a potential immune system modulation platform. The Company has four commercialized products: Pennsaid, Pennsaid 2%, the heated lidocaine/tetracaine patch (HLT Patch, formerly known as Synera) and Pliaglis. The Company is building a portfolio of products for the treatment of pain through internal research and development (R&D) and by in-licensing and acquisition. The Company is also involved in R&D activities with WF10, a chlorite-based immune modulating drug, through Nuvo Research AG.

Ratios

vs
industry
vs
history
PE Ratio 27.86
NRIFF's PE Ratio is ranked lower than
56% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.40 vs. NRIFF: 27.86 )
Ranked among companies with meaningful PE Ratio only.
NRIFF' s PE Ratio Range Over the Past 10 Years
Min: 0.9  Med: 8 Max: 37.86
Current: 27.86
0.9
37.86
Forward PE Ratio 7.18
NRIFF's Forward PE Ratio is ranked higher than
90% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. NRIFF: 7.18 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 3.22
NRIFF's PB Ratio is ranked lower than
57% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. NRIFF: 3.22 )
Ranked among companies with meaningful PB Ratio only.
NRIFF' s PB Ratio Range Over the Past 10 Years
Min: 0.61  Med: 2.14 Max: 41.69
Current: 3.22
0.61
41.69
PS Ratio 2.23
NRIFF's PS Ratio is ranked higher than
58% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. NRIFF: 2.23 )
Ranked among companies with meaningful PS Ratio only.
NRIFF' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 2.85 Max: 32.38
Current: 2.23
0.77
32.38
Price-to-Free-Cash-Flow 119.39
NRIFF's Price-to-Free-Cash-Flow is ranked lower than
89% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.72 vs. NRIFF: 119.39 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NRIFF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.93  Med: 30.52 Max: 162.24
Current: 119.39
5.93
162.24
Price-to-Operating-Cash-Flow 75.97
NRIFF's Price-to-Operating-Cash-Flow is ranked lower than
90% of the 295 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.98 vs. NRIFF: 75.97 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NRIFF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.78  Med: 27.81 Max: 775
Current: 75.97
5.78
775
Current Ratio 4.62
NRIFF's Current Ratio is ranked higher than
75% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. NRIFF: 4.62 )
Ranked among companies with meaningful Current Ratio only.
NRIFF' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 3.72 Max: 25.02
Current: 4.62
0.14
25.02
Quick Ratio 4.03
NRIFF's Quick Ratio is ranked higher than
76% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. NRIFF: 4.03 )
Ranked among companies with meaningful Quick Ratio only.
NRIFF' s Quick Ratio Range Over the Past 10 Years
Min: 0.05  Med: 3.39 Max: 23.62
Current: 4.03
0.05
23.62
Days Inventory 77.40
NRIFF's Days Inventory is ranked higher than
71% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. NRIFF: 77.40 )
Ranked among companies with meaningful Days Inventory only.
NRIFF' s Days Inventory Range Over the Past 10 Years
Min: 75.26  Med: 88.19 Max: 181.84
Current: 77.4
75.26
181.84
Days Sales Outstanding 36.46
NRIFF's Days Sales Outstanding is ranked higher than
84% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. NRIFF: 36.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
NRIFF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.7  Med: 83.12 Max: 104.56
Current: 36.46
19.7
104.56

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.50
NRIFF's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. NRIFF: -8.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NRIFF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -57.9  Med: -12.45 Max: -3.9
Current: -8.5
-57.9
-3.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.63
NRIFF's Price-to-Net-Cash is ranked higher than
65% of the 250 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.84 vs. NRIFF: 5.63 )
Ranked among companies with meaningful Price-to-Net-Cash only.
NRIFF' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.9  Med: 7.44 Max: 949.49
Current: 5.63
0.9
949.49
Price-to-Net-Current-Asset-Value 3.42
NRIFF's Price-to-Net-Current-Asset-Value is ranked higher than
76% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. NRIFF: 3.42 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NRIFF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.84  Med: 4.37 Max: 4030
Current: 3.42
0.84
4030
Price-to-Tangible-Book 3.22
NRIFF's Price-to-Tangible-Book is ranked higher than
53% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. NRIFF: 3.22 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NRIFF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.82  Med: 4.01 Max: 1597.5
Current: 3.22
0.82
1597.5
Price-to-Median-PS-Value 0.79
NRIFF's Price-to-Median-PS-Value is ranked higher than
77% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. NRIFF: 0.79 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NRIFF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 1.67 Max: 140.81
Current: 0.79
0.32
140.81
Earnings Yield (Greenblatt) % -7.80
NRIFF's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. NRIFF: -7.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NRIFF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 16.2  Med: 29.05 Max: 50072.4
Current: -7.8
16.2
50072.4

More Statistics

Revenue (TTM) (Mil) $22.66
EPS (TTM) $ 0.16
Beta-0.45
Short Percentage of Float0.00%
52-Week Range $3.70 - 6.38
Shares Outstanding (Mil)11.50

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 21 22 22 24
EPS ($) 0.64 0.61 0.74 0.81
EPS without NRI ($) 0.64 0.61 0.74 0.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)